1 / 11

3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in GT1 TURQUOISE-II

Phase 3. Compensated Cirrhosis. Treatment Naïve and Treatment Experienced. 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in GT1 TURQUOISE-II. Poordad F, et al. N Engl J Med. 2014;370:1973-82. 3D + Ribavirin in GT1 and Compensated Cirrhosis TURQUOISE- II: Study Design.

pandora-gilmore
Download Presentation

3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in GT1 TURQUOISE-II

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 3 Compensated Cirrhosis Treatment Naïve and Treatment Experienced 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in GT1 TURQUOISE-II Poordad F, et al. N Engl J Med. 2014;370:1973-82.

  2. 3D + Ribavirin in GT1 and Compensated CirrhosisTURQUOISE-II: Study Design Source: Poordad F, et al. N Engl J Med. 2014;370:1973-82.

  3. 3D + Ribavirin in GT1 and Compensated CirrhosisTURQUOISE-II: Regimens 0 12 24 36 Week 3D + Ribavirin Group AN = 208 SVR12 3D + Ribavirin Group BN = 172 SVR12 3D = Paritaprevir-ritonavir-Ombitasvir + Dasabuvir Drug Dosing3D = Paritaprevir-ritonavir-Ombitasvir (150/100/25 mg once daily)+ Dasabuvir: 250 mg twice dailyRibavirin (RBV): weight-based and divided bid (1000 mg/day if < 75kg or 1200 mg/day if ≥ 75kg) Source: Poordad F, et al. N Engl J Med. 2014;370:1973-82.

  4. 3D + Ribavirin in GT1 and Compensated CirrhosisTURQUOISE-II: Results TURQUOISE II: SVR12 by Genotype 1 Subtype 191/208 165/172 124/140 114/121 67/68 50/51 Source: Poordad F, et al. N Engl J Med. 2014;370:1973-82.

  5. 3D + Ribavirin in GT1 and Compensated CirrhosisTURQUOISE-II: Results TURQUOISE II: SVR12 Based on Prior Treatment 81/86 70/74 28/29 23/23 17/18 13/13 65/75 59/62 Source: PoordadF, et al. N Engl J Med. 2014;370:1973-82.

  6. 3D + Ribavirin in GT1 and Compensated CirrhosisTURQUOISE-II: Results for GT1a TURQUOISE II: Genotype 1a SVR12 Based on Prior Treatment 59/64 52/56 14/15 13/13 11/11 10/10 40/50 39/42 Source: PoordadF, et al. N Engl J Med. 2014;370:1973-82.

  7. 3D + Ribavirin in GT1 and Compensated CirrhosisTURQUOISE-II: Results for GT1b TURQUOISE II: Genotype 1b SVR12 Based on Prior Treatment 22/22 18/18 14/14 10/10 6/7 3/3 25/25 20/20 Source: PoordadF, et al. N Engl J Med. 2014;370:1973-82.

  8. 3D + Ribavirin in GT1 and Compensated CirrhosisTURQUOISE-II: Adverse Effects Source: PoordadF, et al. N Engl J Med. 2014;370:1973-82.

  9. 3D + Ribavirin in GT1 and Compensated CirrhosisTURQUOISE-II: Adverse Effects Source: PoordadF, et al. N Engl J Med. 2014;370:1973-82.

  10. 3D + Ribavirin in GT1 and Compensated CirrhosisTURQUOISE-II: Conclusions Source: Poordad F, et al. N Engl J Med. 2014;370:1973-82.

  11. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.

More Related